Literature DB >> 2060703

In vitro development of precursor cells in the myogenic lineage.

S J Kaufman1, M George-Weinstein, R F Foster.   

Abstract

Expression of the muscle-specific integral membrane protein H36 and the intermediate filament protein desmin, detected by immunofluorescence, was used to identify cells at distinct stages in the skeletal myogenic lineage. These proteins were coordinately expressed in cultures of rat hindlimb myoblasts from 17- and 19-day fetuses and newborn pups, and in satellite cells from juveniles. Both H36+ and desmin+ cells were present in cultures from 13.5- and 15-day embryonic hindlimbs, but desmin expression was more prevalent: H36-/desmin+ myoblasts predominate during this early stage of development. H36 was not detected in Day 12 embryo hindlimb bud cells in vivo nor in cultures soon after plating. Initially, only 1% of the Day 12 limb bud cells expressed desmin. When these cells were serially passaged every 3-4 days, cells with all three possible myogenic phenotypes developed: that is, H36+/desmin-, H36+/desmin+, and H36-/desmin+ cells. There was a progressive increase in the frequency of H36+ cells, with 75% of cells positive by passage 6 (Day 27 in vitro). The maximum frequency of cells that expressed desmin occurred in passage 5 (Day 23 in vitro). These results demonstrate that precursors to the cells that express H36 and desmin are present in the 12-day embryo hindlimb bud and that the transition from H36-/desmin- precursors to cells with a myogenic phenotype can occur in vitro. MyoD1 and myogenin were not detected in these cells, suggesting that the initial expression of H36 and desmin in the myogenic lineage may precede and/or is independent of these regulatory proteins. The conversion of precursor cells in the 12-day limb bud to a more advanced stage of development serves to define additional cells in the myogenic lineage. The ability to monitor in vitro these stages of development affords the opportunity to study how they are regulated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060703     DOI: 10.1016/0012-1606(91)90462-c

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  7 in total

1.  alpha7 integrin expressing human fetal myogenic progenitors have stem cell-like properties and are capable of osteogenic differentiation.

Authors:  Nobuaki Ozeki; Moon Lim; Chung-Chen Yao; Mirek Tolar; Randall H Kramer
Journal:  Exp Cell Res       Date:  2006-09-23       Impact factor: 3.905

2.  The beta1 cytoplasmic domain regulates the laminin-binding specificity of the alpha7X1 integrin.

Authors:  Ming-Guang Yeh; Barry L Ziober; Baomei Liu; Galina Lipkina; Ioannis S Vizirianakis; Randall H Kramer
Journal:  Mol Biol Cell       Date:  2003-06-13       Impact factor: 4.138

3.  Melanoma cell adhesion molecule is a novel marker for human fetal myogenic cells and affects myoblast fusion.

Authors:  Massimiliano Cerletti; Michael J Molloy; Kinga K Tomczak; Soonsang Yoon; Marco F Ramoni; Alvin T Kho; Alan H Beggs; Emanuela Gussoni
Journal:  J Cell Sci       Date:  2006-07-11       Impact factor: 5.285

4.  Modulation of satellite cell adhesion and motility following BMP2-induced differentiation to osteoblast lineage.

Authors:  Nobuaki Ozeki; Poonam Jethanandani; Hiroshi Nakamura; Barry L Ziober; Randall H Kramer
Journal:  Biochem Biophys Res Commun       Date:  2006-12-04       Impact factor: 3.575

5.  Lamin A/C and emerin are critical for skeletal muscle satellite cell differentiation.

Authors:  Richard L Frock; Brian A Kudlow; Angela M Evans; Samantha A Jameson; Stephen D Hauschka; Brian K Kennedy
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

6.  H36-alpha 7 is a novel integrin alpha chain that is developmentally regulated during skeletal myogenesis.

Authors:  W K Song; W Wang; R F Foster; D A Bielser; S J Kaufman
Journal:  J Cell Biol       Date:  1992-05       Impact factor: 10.539

7.  Myogenic differentiation of VCP disease-induced pluripotent stem cells: A novel platform for drug discovery.

Authors:  Katrina J Llewellyn; Angèle Nalbandian; Lan N Weiss; Isabela Chang; Howard Yu; Bibo Khatib; Baichang Tan; Vanessa Scarfone; Virginia E Kimonis
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.